HERON THERAPEUTICS, INC. /DE/
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Ashley HinsonHouse · R · IA |
HRTXHERON THERAPEUTICS, INC. /DE/ · Stock |
Sale $1,001 - $15,000 |
Apr 5, 2021 | Mar 31, 2021 | Filing ↗ |
Whale Activity
- Increased50
- New18
- Held39
- Decreased49
- Closed22
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| Rubric Capital Management LP | 30.0M | $9.4M | held |
| Clearline Capital LP | 11.0M | $3.5M | decreased |
| BlackRock, Inc. | 9.8M | $3.1M | decreased |
| TANG CAPITAL MANAGEMENT LLC | 9.0M | $2.8M | increased |
| Velan Capital Investment Management LP | 8.8M | $2.7M | held |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.8M | $2.5M | increased |
| Tejara Capital Ltd | 6.5M | $2.0M | decreased |
| GSA CAPITAL PARTNERS LLP | 5.5M | $1.7M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 4.1M | $1.3M | decreased |
| STATE STREET CORP | 3.2M | $1.0M | decreased |
| UBS Group AG | 2.1M | $661K | decreased |
| AQR CAPITAL MANAGEMENT LLC | 2.0M | $623K | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Hensley Mark EarlChief Operating Officer | Tax withholding | −8,888 | $0.50 | $4K | Aug 6, 2026 | Form 4 ↗ |
| Hensley Mark EarlChief Operating Officer | Option exercise | +31.3K | — | — | Aug 6, 2026 | Form 4 ↗ |
| Hensley Mark EarlChief Operating Officer | Option exercise | +11.8K | — | — | Jul 31, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Tax withholding | −3,326 | $0.50 | $2K | Jul 31, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +11.7K | — | — | Jul 31, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Tax withholding | −3,326 | $0.50 | $2K | Jul 31, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +11.7K | — | — | Jul 31, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +34.8K | — | — | Jul 31, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Tax withholding | −3,348 | $0.50 | $2K | Jul 30, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +11.8K | — | — | Jul 30, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Tax withholding | −3,850 | $0.50 | $2K | Jul 30, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +13.5K | — | — | Jul 30, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +50.0K | — | — | Jul 30, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +13.8K | — | — | Jul 19, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Tax withholding | −1,101 | $0.47 | $517 | Jul 19, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +3,874 | — | — | Jul 19, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Tax withholding | −1,101 | $0.47 | $517 | Jul 19, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +3,874 | — | — | Jul 19, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Tax withholding | −3,555 | $0.38 | $1K | Jun 16, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +12.5K | — | — | Jun 16, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.5M | $2.3M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.7M | $1.6M | 0.00% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.1M | $881K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.6M | $807K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 1.4M | $581K | 0.00% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 912.9K | $290K | 0.00% | Aug 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 861.9K | $274K | 0.00% | Aug 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 537.3K | $229K | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 510.4K | $218K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund SCHWAB CAPITAL TRUST | 413.6K | $205K | 0.00% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list HRTX's shares (CUSIP 427746102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Corporate Lobbying
- FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q3 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q2 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q1 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2025 Q4 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2025 Q3 · HCR, MMM$50K
Filing ↗
Government Contracts
No federal contract awards found for HERON THERAPEUTICS, INC. /DE/.
U.S. Patents
No USPTO patent applications found for HERON THERAPEUTICS, INC. /DE/.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$2.5M | -$11.5M | -$110.6M | -$174.7M | -$217.8M |
| Net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M | -$220.7M |
| Diluted EPS | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 |
| Operating cash flow | -$27.6M | -$22.5M | -$58.8M | -$146.9M | -$203.4M |
| Cash and equivalents | $28.6M | $25.8M | $28.7M | $15.4M | $90.5M |
| Total assets | $255.9M | $233.1M | $222.5M | $251.0M | $305.7M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M |
| Shareholders' equity | $14.3M | -$33.7M | -$34.0M | $13.6M | $77.6M |
As HERON THERAPEUTICS, INC. /DE/ tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
- 1-for-20Reverse splitJan 13, 2014
- 1-for-4Reverse splitMay 25, 2007
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.03, 7.01, 9.01Material agreement · Modification of rights · Reg FD disclosureNov 9, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementSep 29, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.03, 9.01Material agreement · Modification of rightsAug 14, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
EDGAR ↗ - 8-K · Items 3.01, 9.01Delisting noticeJun 25, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 16, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗

